Lilian Tereza Lavras Costallat

Lilian Tereza Lavras Costallat

Auto-generated profile, based on publicly available information

Lilian Tereza Lavras Costallat

Division of Rheumatology, Department of Orthopedics, Rheumatology and Traumatology, Universidade Estadual de Campinas (Unicamp), Campinas, Brazil

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
MUManuel F. Ugarte-Gil
Manuel F. Ugarte-Gil
DWDaniel Wojdyla
Daniel Wojdyla
GPGuillermo J. Pons-Estel
Guillermo J. Pons-Estel
RQRosana Quintana
Rosana Quintana
JGJosé A Gómez-Puerta
José A Gómez-Puerta
BPBernardo A. Pons-Estel.
Bernardo A. Pons-Estel.
Objective.: To determine the predictors of remission and low disease activity state (LDAS) in patients with systemic lupus erythematosus (SLE). Methods.: Three disease activity states were defined: Remission = SLE Disease Activity Index (SLEDAI) = 0 and prednisone ≤ 5 mg/day and/or immunosuppressants (maintenance dose); LDAS = SLEDAI ≤ 4, prednisone ≤ 7.5 mg/day and/or immunosuppressants (maintenance dose); and non-optimally controlled state = SLEDAI > 4 and/or prednisone > 7.5 mg/day and/or immunosuppressants (induction dose). Antimalarials were allowed in all groups. Patients with at least 2 SLEDAI reported and not optimally controlled at entry were included in these analyses. Outcomes were remission and LDAS. Multivariable Cox regression models (stepwise selection procedure) were performed for remission and for LDAS. Results.: Of 1480 patients, 902 were non-optimally controlled at entry; among them, 196 patients achieved remission (21.7%) and 314 achieved LDAS (34.8%). Variables predictive of a higher probability of remission were the absence of mucocutaneous manifestations (HR 1.571, 95% CI 1.064–2.320), absence of renal involvement (HR 1.487, 95% CI 1.067–2.073), and absence of hematologic involvement (HR 1.354, 95% CI 1.005–1.825); the use of immunosuppressive drugs before the baseline visit (HR 1.468, 95% CI 1.025–2.105); and a lower SLEDAI score at entry (HR 1.028, 95% CI 1.006–1.051 per 1-unit decrease). These variables were predictive of LDAS: older age at entry, per 5-year increase (HR 1.050, 95% CI 1.004–1.098); absence of mucocutaneous manifestations (HR 1.401, 95% CI 1.016–1.930) and renal involvement (HR 1.344, 95% CI 1.049–1.721); and lower SLEDAI score at entry (HR 1.025, 95% CI 1.009–1.042). Conclusion.: Absence of mucocutaneous, renal, and hematologic involvement, use of immunosuppressive drugs, and lower disease activity early in the course of the disease were predictive of remission in patients with SLE; older age was predictive of LDAS.

18 June 2024 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
EREdgard Torres dos Reis-Neto
Edgard Torres dos Reis-Neto
LSLuciana Parente Costa Seguro
Luciana Parente Costa Seguro
ESEmilia Inoue Sato
Emilia Inoue Sato
EBEduardo Ferreira Borba
Eduardo Ferreira Borba
EKEvandro Mendes Klumb
Evandro Mendes Klumb
OMOdirlei Andre Monticielo
Odirlei Andre Monticielo
Objective: To develop the second evidence-based Brazilian Society of Rheumatology consensus for diagnosis and treatment of lupus nephritis (LN). Methods: Two methodologists and 20 rheumatologists from Lupus Comittee of Brazilian Society of Rheumatology participate in the development of this guideline. Fourteen PICO questions were defined and a systematic review was performed. Eligible randomized controlled trials were analyzed regarding complete renal remission, partial renal remission, serum creatinine, proteinuria, serum creatinine doubling, progression to end-stage renal disease, renal relapse, and severe adverse events (infections and mortality). The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to develop these recommendations. Recommendations required ≥82% of agreement among the voting members and were classified as strongly in favor, weakly in favor, conditional, weakly against or strongly against a particular intervention. Other aspects of LN management (diagnosis, general principles of treatment, treatment of comorbidities and refractory cases) were evaluated through literature review and expert opinion. Results: All SLE patients should undergo creatinine and urinalysis tests to assess renal involvement. Kidney biopsy is considered the gold standard for diagnosing LN but, if it is not available or there is a contraindication to the procedure, therapeutic decisions should be based on clinical and laboratory parameters. Fourteen recommendations were developed. Target Renal response (TRR) was defined as improvement or maintenance of renal function (±10% at baseline of treatment) combined with a decrease in 24-h proteinuria or 24-h UPCR of 25% at 3 months, a decrease of 50% at 6 months, and proteinuria < 0.8 g/24 h at 12 months. Hydroxychloroquine should be prescribed to all SLE patients, except in cases of contraindication. Glucocorticoids should be used at the lowest dose and for the minimal necessary period. In class III or IV (±V), mycophenolate (MMF), cyclophosphamide, MMF plus tacrolimus (TAC), MMF plus belimumab or TAC can be used as induction therapy. For maintenance therapy, MMF or azathioprine (AZA) are the first choice and TAC or cyclosporin or leflunomide can be used in patients who cannot use MMF or AZA. Rituximab can be prescribed in cases of refractory disease. In cases of failure in achieving TRR, it is important to assess adherence, immunosuppressant dosage, adjuvant therapy, comorbidities, and consider biopsy/rebiopsy. Conclusion: This consensus provides evidence-based data to guide LN diagnosis and treatment, supporting the development of public and supplementary health policies in Brazil.

1 January 2015 in Revista Brasileira de Reumatologia (English Edition)
Verified
Journal Article
Open access
EKEvandro Mendes Klumb
Evandro Mendes Klumb
CSClovis Artur Almeida Silva
Clovis Artur Almeida Silva
CLCristina Costa Duarte Lanna
Cristina Costa Duarte Lanna
ESEmilia Inoue Sato
Emilia Inoue Sato
EBEduardo Ferreira Borba
Eduardo Ferreira Borba
FRFrancinne Machado Ribeiro
Francinne Machado Ribeiro
ObjectiveTo develop recommendations for the diagnosis, management and treatment of lupus nephritis in Brazil.MethodExtensive literature review with a selection of papers based on the strength of scientific evidence and opinion of the Commission on Systemic Lupus Erythematosus members, Brazilian Society of Rheumatology.Results and conclusions(1) Renal biopsy should be performed whenever possible and if this procedure is indicated; and, when the procedure is not possible, the treatment should be guided with the inference of histologic class. (2) Ideally, measures and precautions should be implemented before starting treatment, with emphasis on attention to the risk of infection. (3) Risks and benefits of treatment should be shared with the patient and his/her family. (4) The use of hydroxychloroquine (preferably) or chloroquine diphosphate is recommended for all patients (unless contraindicated) during induction and maintenance phases. (5) The evaluation of the effectiveness of treatment should be made with objective criteria of response (complete remission/partial remission/refractoriness). (6) Angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers are recommended as antiproteinuric agents for all patients (unless contraindicated). (7) The identification of clinical and/or laboratory signs suggestive of proliferative or membranous glomerulonephritis should indicate an immediate implementation of specific therapy, including corticosteroids and an immunosuppressive agent, even though histological confirmation is not possible. (8) Immunosuppressives must be used during at least 36 months, but these medications can be kept for longer periods. Its discontinuation should only be done when the patient could achieve and maintain a sustained and complete remission. (9) Lupus nephritis should be considered as refractory when a full or partial remission is not achieved after 12 months of an appropriate treatment, when a new renal biopsy should be considered to assist in identifying the cause of refractoriness and in the therapeutic decision

1 January 2024 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
SASimone Appenzeller
Simone Appenzeller
LCLilian Lavras Costallat
Lilian Lavras Costallat
MRMarcelo de Carvalho Ramos
Marcelo de Carvalho Ramos
SASamuel de Oliveira Andrade
Samuel de Oliveira Andrade
FRFabiano Reis
Fabiano Reis
A 41-year-old woman with systemic lupus erythematosus (SLE) presented to the outpatient department with progressive 3-month interscapular pain that was refractory to analgesics. The patient’s medications included azathioprine 50 mg, hydroxychloroquine 400 mg, and prednisone 5 mg daily. She reported a weight loss of 7 kg in the previous 2 months but denied experiencing fever or any history of trauma. She lived in a rural area and worked in the agricultural sector. Thoracic spinal radiographs obtained during the initial assessment revealed T7 vertebral collapse and diffuse nodular pulmonary opacities. The patient was hospitalized; chest computed tomography (CT) revealed the presence of diffuse micronodular disease ( Figure 1) and vertebral collapse associated with signs of spondylodiscitis at T6-T7 and T7-T8, which were confirmed by magnetic resonance imaging ( Figures 2 and 3). A T8 paravertebral computed tomography-guided biopsy confirmed the presence of Paracoccidioides spp. The patient was treated with itraconazole 100 mg daily for 3 months, resulting in the complete resolution of infection and a good outcome.

1 May 2012 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Open access
MYMichel A. Yazbek
Michel A. Yazbek
PVPaulo Velho
Paulo Velho
WNWilson Nadruz
Wilson Nadruz
NMNazira Mahayri
Nazira Mahayri
SASimone Appenzeller
Simone Appenzeller
LCLilian Tereza Lavras Costallat
Lilian Tereza Lavras Costallat
Low-molecular-weight heparin-induced skin necrosis can occur as a clinical feature of heparin-induced thrombocytopenia syndrome. Heparin-induced thrombocytopenia and antiphospholipid syndromes have some clinical features in common, including thrombocytopenia and thrombotic events. We describe a 46-year-old woman who developed extensive necrosis in the breast and other sites secondary to the use of enoxaparin after an elective hysterectomy. During the postoperative period, diagnoses of systemic lupus erythematosus and antiphospholipid syndrome were made because of some clinical and laboratory features (seizure, nephritis, bicytopenia, positive nuclear antibody, and positive antiphospholipid antibodies with a previous thrombotic event). The patient's clinical course improved only after corticosteroid therapy and the suspension of enoxaparin. Heparin-induced thrombocytopenia and antiphospholipid syndromes can have platelet factor 4 as a common denominator in their pathogenesis because platelet factor 4 tetramers can bind β2-glycoprotein molecules. This case suggests that use of low-molecular-weight heparins could be more risky in patients with an underlying immune disease and/or could trigger immune reactions that must be analyzed in larger studies.

5 April 2019
Verified
Conference Paper
Open access
PDF file
RFRenan Frittoli
Renan Frittoli
RMRoberto Marini
Roberto Marini
LCLilian Costallat
Lilian Costallat
SASimone Appenzeller
Simone Appenzeller
Background There is evidence that most individuals with Systemic Lupus Erythematosus (SLE) have been born at the end of the winter season, mainly because of the influence of the mother’s exposure to sunlight during pregnancy, possibly affecting vitamin D metabolism. The objective was to evaluate the influence of the birth month in the development of SLE. Methods We included consecutive patients with childhood-onset SLE (cSLE) (age at onset of disease 16 years) and adult-onset SLE (age of onset of disease >16 years) from the Rheumatology outpatient unit in Brazil. The control group consisted of volunteers no history of autoimmune disease. Through the review of medical records the patient‘s date of birth was obtained and the patients were classified according to the months and seasons of the year in which they were born. The results were presented in a descriptive way and the statistical analysis was performed through the chi-square test. For all analyzes p0.05). Conclusions It is believed that the winter season interferes with the development of SLE, especially in cSLE. These results may reinforce the idea that climate can be a contributing factor to the development of cSLE. Funding Source(s): CNPq FAPESP